Traws Pharma, Inc. TRAW
Biotechnology: Pharmaceutical Preparations · IPO 2013 · data as of November 13, 2026
Traws Pharma, Inc. (TRAW) is a healthcare company listed in the US with a market value of about $4M.
Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (3/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -78%.
About Traws Pharma
Traws Pharma is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2013. Revenue went from $800000 in 2014 to $226000 in 2024, a decline of about 11.9% a year. It was profitable in 1 of the last 10 years in our data. Its share count rose by 902% over three years (dilution for shareholders).
Score: 0.6 / 5
Checks passed
- More cash than debt, or low debt to equity
- Interest covered more than 5 times
- Debt below 3 years of free cash flow
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | $226000 | $226000 | $226000 | $226000 | $231000 | $2M | $1M | $787000 | $6M |
| Net income | $9M | -$167M | -$19M | -$19M | -$16M | -$25M | -$22M | -$21M | -$24M | -$20M |
| Free cash flow | -$21M | -$33M | -$18M | — | — | -$23M | -$21M | — | — | — |
| EPS (diluted) | $0.82 | $-35.21 | $-22.57 | $-22.75 | $-24.00 | $-54.25 | $-37.25 | $-124.75 | $-1003.75 | $-1665.00 |
| Net margin | — | -73682.7% | -8384.1% | -8391.1% | -7151.8% | -10890.5% | -985.0% | -1675.3% | -3061.2% | -354.6% |
| ROIC | — | — | -150.3% | -54.8% | -28.3% | -319.8% | -148.1% | -429.6% | — | -435.8% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 1 analysts is $1.00, 298% above the current price; targets range from $1.00 to $1.00; the consensus rating is “none”; expected EPS is $-1.33 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Traws Pharma pay a dividend?
Not currently.
Is Traws Pharma a good stock to buy?
We do not give buy or sell advice. Traws Pharma scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.